Calc Function

    • Calcs that help predict probability of a diseaseDiagnosis
    • Subcategory of 'Diagnosis' designed to be very sensitiveRule Out
    • Disease is diagnosed: prognosticate to guide treatmentPrognosis
    • Numerical inputs and outputsFormula
    • Med treatment and moreTreatment
    • Suggested protocolsAlgorithm

    Disease

    Select...

    Specialty

    Select...

    Chief Complaint

    Select...

    Organ System

    Select...

    Patent Pending

    Log In

    Show
    Forgot your password?
    Log In
    Or create a new account (it's free)

    Forgot Password?

    Enter your email address and we'll send you a link to reset your password.

    Get New Password

    Sign In Required

    To save favorites, you must log in.

    Creating an account is free, easy, and takes about 60 seconds.

    Already have an MDCalc account?

    Login to link your favorites and recently used calcs

    Show
    Forgot your password?
    Log In
    Or continue to Nuance

    Attention COACH STUDY participants:

    The principal investigators of the study request that you use the official version of the modified score here.

    Duval/CIBMTR Score for Acute Myelogenous Leukemia (AML) Survival

    Predicts overall survival in AML patients with relapsed/refractory disease undergoing myeloablative transplant.

    INSTRUCTIONS

    Use in patients with relapsed or refractory active AML for whom hematopoietic stem cell transplant (HSCT) is being considered. Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.

    When to Use
    Pearls/Pitfalls
    Why Use

    • Patients with relapsed or refractory active acute myeloid leukemia AML (i.e., NOT in complete remission), for whom myeloablative hematopoietic stem cell transplant (HSCT) is being considered.

    • Do not use in patients with chronic myelogenous leukemia (CML) in blast crisis.

    • Only busulfan and TBI-based regimens were studied in the derivation; reduced-intensity conditioning (RIC) and fludarabine-based regimens were excluded.

    • Syngeneic and cord blood transplants were also not included in this analysis.

    Use when deciding between HSCT and additional treatment for patients with relapsed or refractory active disease.

    Primary induction failure or duration of first complete remission >6 months
    0
    Duration of first complete remission <6 months
    +1
    Good or intermediate
    0
    Poor
    +1
    HLA identical sibling or well matched or partially matched unrelated
    0
    Mismatched unrelated
    +1
    Related other than HLA identical sibling
    +2
    Absent
    0
    Present
    +1
    90-100
    0
    <90
    +1

    Result:

    Please fill out required fields.

    Next Steps
    Evidence
    Creator Insights
    Dr. Michel Duval

    About the Creator

    Michel Duval, MD, is the medical director of the hematopoietic transplantation and Cell Therapy Program at the Charles-Bruneau Cancer Center, at the Sainte-Justine University Hospital Center in Montreal, Canada. He is also the co-chief of the hemato-oncology department at the Centre Hospitalier Universitaire Sainte-Justine. Dr. Duval’s research focuses primarily on immunotherapy of childhood cancers and cord blood transplant immunology.

    To view Dr. Michel Duval's publications, visit PubMed

    Are you Dr. Michel Duval? Send us a message to review your photo and bio, and find out how to submit Creator Insights!
    MDCalc loves calculator creators – researchers who, through intelligent and often complex methods, discover tools that describe scientific facts that can then be applied in practice. These are real scientific discoveries about the nature of the human body, which can be invaluable to physicians taking care of patients.
    Content Contributors
    • Joseph Maakaron, MD
    Related Calcs
    About the Creator
    Dr. Michel Duval
    Are you Dr. Michel Duval?
    Also from MDCalc...
    Related Calcs
    Content Contributors
    • Joseph Maakaron, MD